Janux Therapeutics, Inc.
JANX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $0 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 31% | -6.1% | 136.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 80.5% | 75.8% | 90.2% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -914.1% | -878.7% | -769.3% | -902.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -651.6% | -721.2% | -732.2% | -898.3% |
| EPS Diluted | -1.28 | -1.32 | -1.52 | -0.79 |
| % Growth | 3% | 13.2% | -92.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |